IC
GLUE icon

Ikarian Capital’s Monte Rosa Therapeutics GLUE Stock Holding History

Ikarian Capital’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-136,575
Closed -$634K – 160
2025
Q1 		$634K Sell
136,575
-175,000
-56% -$1.07M 0.08% 107
2024
Q4 		$2.16M Sell
311,575
-18
-0% -$135 0.29% 77
2024
Q3 		$1.65M Buy
+311,593
New +$1.57M 0.23% 77

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ikarian Capital's GLUE Position: Q2 2025 in Review

Ikarian Capital sold out of Monte Rosa Therapeutics (GLUE) in Q2 2025, closing a stake of 136,575 shares — an estimated $634K sold.

Ikarian Capital first reported a position in GLUE in Q3 2024 and held it in 3 quarters. The position peaked at $2.16M in Q4 2024. 116 funds tracked by Wall St. Rank hold GLUE as of Q2 2025.

  • Ikarian Capital reported no remaining Monte Rosa Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Ikarian Capital sold 136,575 Monte Rosa Therapeutics shares in Q2 2025, an estimated $634K.
  • Ikarian Capital first reported a position in Monte Rosa Therapeutics in Q3 2024 and held it in 3 quarters.
  • Ikarian Capital's Monte Rosa Therapeutics position peaked at $2.16M in Q4 2024.
  • 116 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2025.

Based on Ikarian Capital's 13F filing for Q2 2025, filed 14 Aug 2025.